DIRS.INFO The most relevant business & tech news

☆ 'A comeback in the making': UBS expects these under-the-radar European stocks to soar
▼ + stars: | 2023-09-08 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +3 min

UBS has named a raft of European small and midcap stocks it says are staging a "comeback in the making" this year. Smaller European stocks returned 0.5% in July and August, outperforming the 1.7% contraction logged by large caps in the same period, the Swiss investment bank noted. On average, stocks on UBS' list of small and mid-cap stocks were up 6.6% year-to-date, beating the MSCI European Smallcap Index by 1.2 percentage points, according to the bank. Stock picks Italian cement and ready-mix company Buzzi is among UBS' top picks, given its year-to-date performance of 53.4%. New on the radar UBS' list has also undergone a refresh to include three new stocks: Galenica , SIG Group and Talgo.

Persons: Knorr, Hugo Boss, Galenica Organizations: UBS, Stock, Bremse, SIG Group, Swiss pharma, SIG Locations: Swiss

One of the nation's largest grocery chains is the latest company to agree to settle lawsuits over the U.S. opioid crisis. In a deal announced Friday, the Kroger Co. would pay up to $1.4 billion over 11 years. Kroger currently has stores in 35 states — virtually everywhere save the Northeast, the northern plains and Hawaii. Over the past eight years, prescription drug manufacturers, wholesalers, consultants and pharmacies have proposed or finalized opioid settlements totaling more than $50 billion, including at least 12 others worth more than $1 billion. “Kroger has long served as a leader in combatting opioid abuse and remains committed to patient safety,” the company said.

Persons: Kroger, —, Jayne Conroy, ”, overprescribing, Conroy, “ Kroger, OptumRx Organizations: Kroger, U.S, Supreme, Purdue Pharma, Associated Press, Albertsons, Pharmacy Locations: Hawaii, New Mexico, West Virginia, U.S

☆ Pharma investors should strategize trades around obesity drug offerings, says Grasso Global CEO
▼ + stars: | 2023-09-08 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPharma investors should strategize trades around obesity drug offerings, says Grasso Global CEOSteve Grasso, Grasso Global CEO, joins 'Power Lunch' to discuss how to trade the news of Kroger's opioid settlement, momentum growing in the biotech sector, and how Snowflake could benefit from AI.

Persons: Grasso, Steve Grasso Organizations: Email Pharma, Grasso Global

☆ Kelly Evans: Why China is turning into a liability for American companies
▼ + stars: | 2023-09-07 | by ( Kelly Evans | ) www.cnbc.com time to read: +4 min

Companies with high China exposure have been underperforming since early 2022, the firm notes. The tech sector actually has the largest sales exposure, with roughly 15% coming from China, compared with about 7.5% for the S&P 500 overall. Other particularly vulnerable industries include autos, with Tesla's high China exposure driving the industry average above 20% for sales to China, and Tesla shares are still 40% below their late 2021 highs. Autos are also one of the industries China is leaning hard on to drive its global exports, as its BYD has become the world's biggest electric car maker. Plus, certain luxury retail brands and myriad other industries from pharma to energy face trouble if their China exposure turns from a blessing to a curse.

Persons: China's, Piper Sandler, Derek Scissors, Xi Jinping, —, Kelly Evans Organizations: CNBC, Washington , D.C, Starbucks, Apple, Bloomberg, Micron, pharma Locations: China, Beijing, Washington ,, Taiwan

☆ Tech is an overvalued trade that needs to correct, says RBC's Lori Calvasina
▼ + stars: | 2023-09-07 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTech is an overvalued trade that needs to correct, says RBC's Lori CalvasinaLori Calvasina, RBC Capital Markets head of U.S. equity strategy, joins 'Squawk on the Street' to discuss markets closing the growth gap in tech, reasonable valuations in pharma benefiting from the labor backdrop, ten-year yield gains adding caution to equity investors.

Persons: RBC's Lori Calvasina Lori Calvasina Organizations: Tech, RBC Capital Markets, pharma

☆ VC Ford Smith used psychedelics and biohacking to pull himself out of a deep depression. Here's why he's backing more startups in the space.
▼ + stars: | 2023-09-07 | by ( Samantha Stokes | ) www.businessinsider.com time to read: +7 min

His experience inspired him to focus his investment firm on backing psychedelic startups. But VCs, including Smith, are still betting big on startups in the space that seem especially promising. It wasn't until he tried psychedelics — including Ayahuasca, a plant-derived hallucinogenic drink, and iboga, an African root bark — that his mental health finally improved. Energized by his own experience, Smith reworked his cannabis-focused VC firm Ultranative into a one-stop-shop for psychedelic startups. Smith and Ultranative are far from the only investors pumping money into psychedelic startups.

Persons: Ford Smith, wean, South America —, Ayahuasca, Ultranative, Smith, didn't, Lyme, psychedelics, Rick Doblin, he's Organizations: innovating, Venture, Anonymous, Multidisciplinary Association for Psychedelic Studies, pharma, FDA, PsyMed Ventures, Lionheart Ventures, Iter Investments, Neo Kuma Ventures, Therapeutics Locations: Austin, South America, U.S, Oregon, Colorado, psychedelics, Texas, Los Angeles, Massachusetts

Sept 6 (Reuters) - Bristol Myers Squibb (BMY.N) has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years after it should have faced generic competition. A spokesperson for Bristol Myers did not immediately respond to a request for comment. Pomalyst is a top seller for Bristol Myers, bringing in nearly $3.5 billion out of $46.16 billion of its total revenue last year. The drug was developed by Celgene, a company acquired by Bristol Myers in 2019. The generic companies, which are also named as defendants in the lawsuit, did not immediately respond to requests for comment.

Persons: Pomalyst, Bristol Myers, Celgene, Brendan Pierson, Alexia Garamfalvi, Bill Berkrot Organizations: Bristol Myers Squibb, Louisiana, Pomalyst, Bristol, Celgene, U.S . Patent, Teva Pharmaceutical Industries, Aurobindo Pharma, Breckeridge Pharmaceutical, Natco Pharma, Thomson Locations: Manhattan, New York

☆ The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals
▼ + stars: | 2023-09-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

That includes the agency's examination of Pfizer 's proposed $43 billion purchase of cancer drug developer Seagen . Some also speculated that the restrictions imposed on Amgen as part of the settlement could have implications for other deals. The FTC's lawsuit against Amgen in May was the agency's first legal challenge to a pharmaceutical buyout in 14 years. The settlement agreement prohibits Amgen from bundling any of its products with two of Horizon's blockbuster drugs, among other restrictions. Still, some analysts said the restrictions suggest the FTC could apply similar rules to other buyouts in the future.

Persons: Amgen, William Blair, Matt Phipps, Robyn Karnauskas, baring, Nathan Ray, West, Biden, Evan Seigerman Organizations: Federal Trade Commission, Horizon Therapeutics, Pfizer, FTC, West Monroe, Amgen, Pharmaceutical, Pharma, BMO Capital Locations: Amgen

☆ The obesity drug boom is just getting started: podcast
▼ + stars: | 2023-09-05 | by ( Aimee Donnellan | ) www.reuters.com time to read: +1 min

A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing RightsLONDON, Sept 5 (Reuters Breakingviews) - Over 1 bln people are obese, the WHO reckons. Denmark’s Novo Nordisk is ahead of the pharma pack with its Wegovy weight-loss drug. Listen to the podcastFollow @aimeedonnellan on XSubscribe to Breakingviews’ podcasts, Viewsroom and The Exchange. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Victoria Klesty, Lars Jorgensen, Oliver Taslic Organizations: REUTERS, Reuters, WHO, Denmark’s, Denmark’s Novo Nordisk, pharma, Thomson Locations: Oslo, Norway, Victoria, Denmark’s Novo

☆ J&J’s $40 Billion Split-Off Sets Stage for Pharma, Medical Tech Expansion
▼ + stars: | 2023-09-04 | by ( Mark Maurer | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/j-js-40-billion-split-off-sets-stage-for-pharma-medical-tech-expansion-817701c1

Persons: Dow Jones Organizations: pharma

☆ How Novartis’s CEO Learned From His Mistakes and Got Help From an Unlikely Quarter
▼ + stars: | 2023-09-03 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/pharma/how-novartiss-ceo-learned-from-his-mistakes-and-got-help-from-an-unlikely-quarter-b087ebbb

Persons: Dow Jones Organizations: pharma

☆ 'Robot pills' could one day help patients avoid needles. The stocks are cheap, but risky
▼ + stars: | 2023-09-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

That's where a number of early-stage drug delivery companies come in — and most are flying under investors' radar. Drug delivery tends to be a "roll-up sector," explained Edward Nash, an analyst at Canaccord Genuity. Nash recently looked at four companies operating in drug delivery: Rani Therapeutics , Biora Therapeutics , Avalyn Pharma and Elektrofi. At the moment, the most effective GLP-1 medications for weight loss are delivered via a subcutaneous injection. The verstility of the Rani pill also is encouraging, according to Harrison, since it could be used with a wide range of drugs.

Persons: that's, Edward Nash, Nash, Rani, FactSet, Talat Imran, Eli Lilly, Evercore, Lilly, Genuity's Nash, Julian Harrison, Rani's, Harrison, Cantor Fitzgerald, Olivia Brayer, Imran, We're Organizations: Big Pharma, Therapeutics, Biora Therapeutics, Avalyn Pharma, CNBC, Novo Nordisk, Novo, European Union, Food and Drug Administration, Celltrion Locations: —

As they do every summer, publicly traded companies posted their second-quarter results while Americans were baring their bodies on the beach. But this year, the timing was apt. On several earnings calls in August, chief executives reassured investors that the Ozempic revolution had not left them in the dust, and that they could somehow share in the blazing success of new diabetes and weight loss drugs. “We will continue to study this,” Michael Johnson, the chief executive of the nutritional supplement maker Herbalife, told investors. “And when we see an opportunity to capitalize on it, we will.”In theory, that opportunity — both for making profits and for losing fortunes — could be vast not only for the companies behind these drugs but also for some in completely different industries.

Persons: baring, ”, Dan R, “, ” Michael Johnson, — Locations: Chard

☆ Opinion | The Promise and Risk of Biden’s War on Drug Prices
▼ + stars: | 2023-09-01 | by ( Peter Coy | ) www.nytimes.com time to read: +2 min

In a textbook free market, “fair” is whatever the market will bear. But these drugs don’t fit that model. Patents protect them from competition, allowing their producers to price them high. On the other hand, because of their high upfront development costs, pricing the drugs very low, at marginal cost, would be unrealistic. If that’s all the manufacturers earned from them, they would have no incentive to stay in business and develop new drugs.

Persons: Biden, Seshamani — Organizations: Big Pharma, pharma, Producers

☆ Pernod Ricard shares face a lengthy dry spell
▼ + stars: | 2023-08-31 | by ( ) www.reuters.com time to read: +2 min

A glass of cognac is pictured on a bar in the Manhattan borough of New York City, November 13, 2015. REUTERS/Mike Segar Acquire Licensing RightsLONDON, Aug 31 (Reuters Breakingviews) - Pernod Ricard (PERP.PA) shareholders have few reasons to cheer. The owner of Mumm champagne and Absolut Vodka said that China’s property crunch was making wholesalers cautious and keeping punters out of nightclubs. China has been a key source of growth for drink-makers: helped by Asia, Pernod Ricard’s sales outside of Europe and the Americas grew 17% in 2023. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Mike Segar, Pernod Ricard, Mumm, Remy Cointreau, Aimee Donnellan, Mukesh Ambani’s, Neil Unmack, Oliver Taslic Organizations: REUTERS, Reuters, Investors, Pernod, Diageo, X, Thomson Locations: Manhattan, New York City, U.S, China, Asia, Europe, Americas

☆ Adani fault lines raise bar for India’s regulator
▼ + stars: | 2023-08-31 | by ( ) www.reuters.com time to read: +2 min

Indian billionaire Gautam Adani speaks during an inauguration ceremony after the Adani Group completed the purchase of Haifa Port earlier in January 2023, in Haifa port, Israel January 31, 2023. It was a hunt an Indian panel probing allegations of stock manipulation warned might be "a journey without a destination". Adani on Thursday rejected OCCRP’s claims, saying they are based on decade-old closed cases. Shares of Adani Total Gas (ADAG.NS), a joint venture with France’s Total, and Adani Power (ADAN.NS) and Adani Enterprises (ADEL.NS) fell 2.5%, 3.5% and 3% respectively. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Gautam Adani, Amir Cohen, Gautam, Hindenburg, Madhabi Puri, she’s, Nasser Ali Shaban Ahli, Taiwan’s Chang Chung, Ling, Vinod Adani, Gautam Adani’s, Adani, OCCRP’s, Mukesh Ambani’s, Didi, Antony Currie, Thomas Shum Organizations: Adani Group, Haifa Port, REUTERS, Rights, Reuters, India’s Securities, Exchange Board of India, United Arab Emirates, France’s, Adani Enterprises, X, Thomson Locations: Haifa, Israel, Madhabi Puri Buch, Una

Suntory Beverage & Food Ltd.'s chief executive Makiko Ono speaks during an interview with Reuters at the company headquarters in Tokyo, Japan December 15, 2022. REUTERS/Issei Kato/File Photo Acquire Licensing RightsTOKYO, Aug 30 (Reuters) - Japan's Suntory Beverage & Food (2587.T) sees Australia as a model for integrating canned alcoholic drinks into offerings in other global markets, Chief Executive Makiko Ono said. As Japan's second-biggest domestic maker of soft drinks, Suntory Beverage has traditionally focused on non-alcohol offerings under the umbrella of global spirits maker Suntory Group. In taking the top job at Suntory Beverage in April, Ono became the first woman to head a Japanese listed company valued at more than 1 trillion yen ($6.83 billion). But the record was soon broken when Yumiko Takano became chief executive of Oriental Land (4661.T), the operator of Tokyo Disneyland, in June.

Persons: Makiko Ono, Issei Kato, Japan's, Ono, Yumiko Takano, Rocky Swift, Clarence Fernandez Organizations: Suntory Beverage & Food Ltd, Reuters, REUTERS, Rights, Japan's Suntory Beverage & Food, Suntory Beverage, Suntory Group, Suntory Oceania, Suntory, Oriental, Thomson Locations: Tokyo, Japan, Australia, New Zealand, Australia's, Brisbane, Europe, Japanese

☆ Drug Price Controls Mean Slower Cures
▼ + stars: | 2023-08-30 | by ( The Editorial Board | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/drug-price-controls-medicare-joe-biden-inflation-reduction-act-pharma-8a38c333

Persons: Dow Jones Organizations: 8a38c333

☆ Medicare wants to cut the price on an Eli Lilly drug. What it means for LLY shares
▼ + stars: | 2023-08-30 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly's revenue from Jardiance — which it markets alongside privately held German biotech firm Boehringer Ingelheim — is likely to suffer due to Medicare negotiations. Compared to those growth drivers, Jardiance is a minor character in the Eli Lilly investment story. However, the deceleration is not entirely due to likely lower realized prices from Medicare negotiations. Eli Lilly looks "relatively protected" from early Medicare negotiations, BMO's Seigmerman said. Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023.

Persons: Eli Lilly, Biden, Myers Squibb, Johnson, Eli Lilly's, —, Evan Seigerman, Seigerman, BMO's Seigmerman, Lilly, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: pharma, Myers, Club, Johnson, Medicare, donanemab, Bank of America, FactSet, Mounjaro, Merck, Constitution, Wall Street, Bristol Myers Squibb, BMO Capital, CNBC, Services, drugmakers, and Drug Administration, FDA, Trulicity, Bloomberg, Getty Locations: Bristol, U.S, Indianapolis , Indiana

☆ 'Pharma Bro' Martin Shkreli claims that he's made more than a dozen accounts on X, but Elon Musk keeps taking them down
▼ + stars: | 2023-08-30 | by ( Grace Dean | ) www.businessinsider.com time to read: +3 min

Martin Shkreli claims that under Elon Musk's leadership more than a dozen of his X accounts have been taken down. In total, he's tried to create up to 20 new accounts since his original was suspended in 2017, he told Fox Business. AdvertisementAdvertisementSo-called "Pharma Bro" Martin Shkreli claims that he's made himself more than a dozen accounts on the social-media platform X since Elon Musk took over, but that the site has subsequently taken them all down. "Elon preaches free speech, but his actions are showing the opposite," Shkreli told Fox Business. Shkreli told Fox Business that it was a "teasing war" and a "silly mistake."

Persons: Martin Shkreli, Elon, he's, Shkreli, Bro, Elon Musk, he'd, Musk, Daraprim, Letitia James, Kanye, Laura Loomer, Lauren Duca, Grimes Organizations: Fox Business, Morning, Elon, Twitter, Federal Trade Commission, New York, Facebook

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. Catalent named three pharma industry executives and a senior Elliott executive to its board and said John Greisch, who has served on the board since 2018, will become executive chairman. Elliott, whose stake in Catalent became public last month, has been engaging with the company behind the scenes for months. Two of the directors were picked by Elliott, while two were mutually agreed by Elliott and Catalent. Catalent is also forming a new strategic and operational review committee which Greisch will chair.

Persons: Yves Herman, Elliott, Catalent, Alessandro Maselli, John Greisch, Max, William Blair, Maselli, Steven Barg, Goldman Sachs, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Greisch, Merck KGaA, Svea Herbst, Bayliss, Maggie Fick, Sriparna Roy, Shinjini Ganguli, Catherine Evans, Mike Harrison Organizations: REUTERS, Catalent Inc, Elliott Investment Management, Reuters, Novo, pharma, U.S . Food, Drug Administration, Pfizer, Johnson, Catalent, Svea, Thomson Locations: Brussels, Belgium, ., Danish, Novo, United States, Catalent, GLP, Boston, London, Bengaluru

☆ Expensive Drugs From Pfizer, Other Companies Targeted for First U.S. Price Negotiations
▼ + stars: | 2023-08-29 | by ( Jared S. Hopkins | Stephanie Armour | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/pharma/expensive-drugs-from-pfizer-other-companies-targeted-for-first-u-s-price-negotiations-9942b20b

Persons: Dow Jones Organizations: pfizer

☆ Expensive Drugs Targeted for First U.S. Price Negotiations
▼ + stars: | 2023-08-29 | by ( Jared S. Hopkins | Stephanie Armour | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/pharma/expensive-drugs-from-pfizer-other-companies-targeted-for-first-u-s-price-negotiations-9942b20b

Persons: Dow Jones Organizations: pfizer

☆ 3M’s $6 bln earplugs settlement is a little sticky
▼ + stars: | 2023-08-29 | by ( ) www.reuters.com time to read: +2 min

A variety of 3M products are pictured at an Orchard Supply Hardware store in Pasadena, California U.S., January 24, 2017. REUTERS/Mario Anzuoni Acquire Licensing RightsNEW YORK, Aug 29 (Reuters Breakingviews) - 3M’s (MMM.N) latest legal settlement includes some curious wrinkles. Moreover, the earplugs agreement is conditioned on 98% participation from what is now roughly 250,000 claimants. The $60 billion company is trying to project the idea it’s getting past its legal entanglements, but the reality is a little stickier. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Mario Anzuoni, Scotchgard, Jeffrey Goldfarb, Mukesh Ambani’s, Didi, Lauren Silva Laughlin, Sharon Lam Organizations: Supply, Pasadena , California U.S, REUTERS, Reuters, Aearo Technologies, X, Thomson Locations: Pasadena , California

☆ These are the top 10 things to watch in the stock market Tuesday
▼ + stars: | 2023-08-29 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Oracle (ORCL) upgraded to buy from neutral at UBS with a price target of $140. Piper Sandler increases its Broadcom (AVGO) price target to $925 from $830 ahead of earnings Thursday after the bell. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: telco, Corie Barry, Piper Sandler, Bernstein, Jim Cramer's, Jim Cramer, Jim, Marlena Sloss Organizations: Oracle, UBS, Nvidia, Investing, Nasdaq, Verizon, Citi, underperform, Biden Administration, Medicare, pharma, DuPont, Broadcom, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: Airbnb, Salesforce, San Francisco , California

Search resuls for: "PHARMA"

25 mentions found